Kaye v. Merck & Co., Inc.

CourtDistrict Court, D. Connecticut
DecidedMarch 27, 2020
Docket3:10-cv-01546
StatusUnknown

This text of Kaye v. Merck & Co., Inc. (Kaye v. Merck & Co., Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kaye v. Merck & Co., Inc., (D. Conn. 2020).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

ROGER H. KAYE, et al., : : Plaintiffs, : : v. : CASE NO. 3:10-CV-1546(RNC) : MERCK & CO., INC., et al., : : Defendants. :

RULING AND ORDER

On April 28, 2010, Dr. Roger Kaye’s office received a fax inviting him to “participate in [a] telesymposium on important clinical information about schizophrenia and bipolar I disorder.” The fax was sent by MedLearning, Inc. (“MedLearning”) pursuant to a contract with Merck & Co., Inc. (“Merck”).1 Kaye and his office (together, the “plaintiffs”) have sued Merck and MedLearning (together, the “defendants”), purporting violations of the Telephone Consumer Protection Act (“TCPA”), 47 U.S.C. § 447, as well as of Conn. Gen. Stat. § 52- 570c. Plaintiffs have moved for summary judgment. For reasons explained below, I agree with defendants that plaintiffs consented to the receipt of the fax. Accordingly, plaintiffs’

1 The contract was actually entered into by Schering Corporation, a predecessor to Merck. This ruling and order will follow the parties’ convention of simply referring to Merck. motion for summary judgment is denied. Moreover, because no material facts are in dispute and because I conclude that plaintiffs cannot maintain their TCPA or state law claims as a

matter of law, summary judgment will be granted in favor of the defendants.2 I. Background A. Factual History In December 2009, Merck hired MedLearning to manage a series of telesymposia discussing schizophrenia, bipolar disorder, and the use of Saphris, a nongeneric drug used to treat these conditions. As part of the agreement between Merck and MedLearning, the latter was responsible for “overall program management” of the telesymposia, including, inter alia, “recruit[ing] all participants from the list provided by the client.” ECF No. 192-1, at 5.

To recruit physicians to participate, MedLearning employed callers to telephone physicians on a list provided by Merck.

2 The plaintiffs attempted to pursue an interlocutory appeal of my decision denying their motion for class certification, which the Second Circuit denied. As a result, the case in its current posture involves no more than a single alleged TCPA violation, meaning that the amount in controversy is, according to plaintiffs, $5,000. Granting summary judgment without awaiting a motion by the defendants serves the parties’ interests in moving this case to entry of an appealable judgment so that the class certification issue can be litigated before the Second Circuit. The callers were instructed to request permission to send a fax invitation to the telesymposium using the following script: Hello, my name is ___________ and I am calling from MedLearning to invite Dr. __________ to participate in a telesymposium, sponsored by Merck, entitled Important Clinical Information about Schizophrenia and Bipolar Disorder. We have several dates and times available. . . . May I fax an invitation? If Yes obtain the fax number. (Request the name of the person giving permission and mark on record.) Thank you for your time. We will fax the invitation.

On April 28, 2010, a MedLearning representative called Dr. Kaye’s office and reached plaintiffs’ answering service. The representative used the above script and was affirmatively given permission to fax the invitation. Later that same day, MedLearning faxed the invitation to plaintiffs’ fax machine. The invitation itself is titled “Important Clinical Information about Schizophrenia and Bipolar I Disorder.” Immediately under the title, in large typeface, are the words “You are invited!” and the Merck logo and name. Farther down, the invitation states: “This speaker program is sponsored and provided by Merck,” “The presenter is speaking on behalf of Merck,” and “The content of this speaker program is consistent with FDA labeling and advertising regulations.” The invitation stated that the recipient could be “removed from the fax list for this program,” either by initialing and returning the form by fax or by calling a phone number. ECF No. 192-3, at 10. Plaintiffs allege that their fax machine used paper to print out the invitation, the machine was occupied while the invitation was being transmitted, and the receipt of the

invitation annoyed Dr. Kaye and wasted his time. For present purposes, these allegations are accepted as true and construed most favorably to plaintiffs. B. Procedural History Plaintiffs filed this suit on September 29, 2010. Discovery was broadly stayed except for discovery relevant to the class certification issue. On January 26, 2014, I ruled that the stay would remain in effect as to any additional discovery pending the outcome of proceedings before the Federal Communications Commission concerning the Commission’s regulation of faxes under the TCPA. See ECF No. 114. The FCC issued an order on October 30, 2014, and both Merck and Kaye were among

those petitioning the D.C. Circuit for review. On March 31, 2017, the D.C. Circuit vacated the FCC’s order, holding that the FCC lacked authority to require businesses to include opt-out notices on solicited faxes. See ECF No. 143; Bais Yaakov of Spring Valley v. FCC, 852 F.3d 1078 (D.C. Cir. 2017). On March 29, 2019, I granted defendants’ motion to strike the complaint’s class allegations, holding that “[d]efendants have demonstrated that these claims do not provide a basis for certifying a class because, in view of the consent protocol used by MedLearning, determining whether a recipient consented to receive a fax would require an individualized inquiry.” ECF No. 171. Plaintiffs sought to appeal the ruling to the Second

Circuit, see ECF No. 176, and were rebuffed, with the Second Circuit concluding that “an immediate appeal is not warranted,” see ECF No. 179. On October 30, 2019, plaintiffs filed a motion for summary judgment, which is now ripe for adjudication. II. Legal Standards Summary judgment is appropriate when “the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving part is entitled to judgment as a matter of law.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 247 (1986) (quoting Fed. R. Civ. P. 56(c)). “Disputed legal questions present nothing for

trial and are appropriately resolved on a motion for summary judgment.” FDIC v. Haines, 3 F. Supp. 2d 155, 159 (D. Conn. 1997) (quoting Flair Broadcasting Corp. v. Powers, 733 F. Supp. 179, 184 (S.D.N.Y. 1990)); see also Schoenefeld v. Schneiderman, 821 F.3d 273,278-79 (2d Cir. 2016) (noting that “purely legal questions” are “particularly conducive to disposition by summary judgment”). It is occasionally, albeit rarely, appropriate for a court to enter summary judgment against a moving party. See Bridgeway Corp. v. Citibank, 201 F.3d 134, 139-40 (2d Cir. 2000). Before doing so, a court must be sure that there is no “indication that the moving party might otherwise bring forward evidence that

would affect the . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

NetJets Aviation, Inc. v. LHC COMMUNICATIONS, LLC
537 F.3d 168 (Second Circuit, 2008)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Ramsey v. Coughlin
94 F.3d 71 (Second Circuit, 1996)
Raymond W. Snider v. Dr. Melindez
199 F.3d 108 (Second Circuit, 1999)
Flair Broadcasting Corp. v. Powers
733 F. Supp. 179 (S.D. New York, 1990)
Federal Deposit Insurance v. Haines
3 F. Supp. 2d 155 (D. Connecticut, 1997)
Schoenefeld v. Schneiderman
821 F.3d 273 (Second Circuit, 2016)
Physicians Healthsource, Inc. v. Stryker Sales Corp.
65 F. Supp. 3d 482 (W.D. Michigan, 2014)
Payton v. Kale Realty, LLC
164 F. Supp. 3d 1050 (N.D. Illinois, 2016)
Gorss Motels, Inc. v. Am. Tex-Chem Corp.
323 F. Supp. 3d 330 (D. Connecticut, 2018)
Bais Yaakov v. Eductl. Testing Service
367 F. Supp. 3d 93 (S.D. Illinois, 2019)
Physicians Healthsource, Inc. v. A-S Medication Solutions LLC
324 F. Supp. 3d 973 (E.D. Illinois, 2018)
Agne v. Papa John's International, Inc.
286 F.R.D. 559 (W.D. Washington, 2012)
Coach Leatherware Co. v. Anntaylor, Inc.
933 F.2d 162 (Second Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Kaye v. Merck & Co., Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kaye-v-merck-co-inc-ctd-2020.